Polar Capital’s Aclaris Therapeutics ACRS Stock Holding History

Polar Capital’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,443,920	Closed	-$21M	–	259
2018 Q3	$21M	Sell	1,443,920 -206,795	-13%	-$3.54M	0.18%	149
2018 Q2	$33K	Hold	1,650,715	–	–	0.2%	106
2018 Q1	$28.9M	Buy	1,650,715 +310,784	+23%	+$6.59M	0.29%	119
2017 Q4	$33M	Sell	1,339,931 -6,118	-0.5%	-$149K	0.34%	92
2017 Q3	$34.7M	Hold	1,346,049	–	–	0.39%	86
2017 Q2	$36.5M	Buy	1,346,049 +375,000	+39%	+$10.2M	0.49%	69
2017 Q1	$29M	Buy	+971,049	New	+$28M	0.43%	81

Other funds holding ACRS

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Polar Capital's ACRS Position: Q4 2018 in Review

Polar Capital sold out of Aclaris Therapeutics (ACRS) in Q4 2018, closing a stake of 1,443,920 shares — an estimated $21M sold.

Polar Capital first reported a position in ACRS in Q1 2017 and held it in 7 quarters. The position peaked at $36.5M in Q2 2017. 99 funds tracked by Wall St. Rank hold ACRS as of Q4 2018.

Polar Capital reported no remaining Aclaris Therapeutics position as of Q4 2018 after selling out during the quarter.
Polar Capital sold 1,443,920 Aclaris Therapeutics shares in Q4 2018, an estimated $21M.
Polar Capital first reported a position in Aclaris Therapeutics in Q1 2017 and held it in 7 quarters.
Polar Capital's Aclaris Therapeutics position peaked at $36.5M in Q2 2017.
99 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2018.

Based on Polar Capital's 13F filing for Q4 2018, filed 14 Feb 2019.